Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration
| العنوان: | Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration |
|---|---|
| المؤلفون: | Oriol Dols-Icardo, Joel H. Kramer, Neus Falgàs, Alberto Lleó, Nicole Rogers, Rafael Blesa, Sergi Borrego-Écija, Albert Lladó, Miguel A Santos-Santos, Daniel Alcolea, Adam L. Boxer, Sheila Castro-Suarez, Maria Luisa Gorno Tempini, Adit Friedberg, Raquel Sánchez-Valle, Jordi Clarimón, David C. Perry, Howard J. Rosen, Aldo Quattrone, Amy Wolf, Andrea Quattrone, Bruce L. Miller, Salvatore Spina, Ophir Keret, Salvatore Nigro, Didem Oz, Lea T. Grinberg, Ignacio Illán-Gala, Yann Cobigo, William W. Seeley, Juan Fortea, Gil D. Rabinovici, Kyan Younes |
| المصدر: | JAMA network open 4 (2021): e211290. doi:10.1001/jamanetworkopen.2021.1290 info:cnr-pdr/source/autori:Ignacio Illán-Gala 1 2, Neus Falgàs 2 3, Adit Friedberg 2, Sheila Castro-Suárez 2, Ophir Keret 2, Nicole Rogers 2, Didem Oz 2, Salvatore Nigro 4, Andrea Quattrone 5, Aldo Quattrone 4 6, Amy Wolf 7, Kyan Younes 7, Miguel Santos-Santos 1, Sergi Borrego-Écija 3, Yann Cobigo 7, Oriol Dols-Icardo 1, Albert Lladó 3, Raquel Sánchez-Valle 3, Jordi Clarimon 1, Rafael Blesa 1, Daniel Alcolea 1, Juan Fortea 1, Alberto Lleó 1, Lea T Grinberg 7, Salvatore Spina 7, Joel H Kramer 7, Gil D Rabinovici 7, Adam Boxer 7, Maria Luisa Gorno Tempini 7, Bruce L Miller 7, William W Seeley 7, Howard J Rosen 7, David C Perry 7/titolo:Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration/doi:10.1001%2Fjamanetworkopen.2021.1290/rivista:JAMA network open/anno:2021/pagina_da:e211290/pagina_a:/intervallo_pagine:e211290/volume:4 Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona JAMA Network Open |
| بيانات النشر: | American Medical Association, Chicago IL, Stati Uniti d'America, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Clinical Dementia Rating, Atrophy, Internal medicine, mental disorders, medicine, Humans, Longitudinal Studies, Original Investigation, Aged, Cerebral atrophy, Clinical Deterioration, Receiver operating characteristic, medicine.diagnostic_test, business.industry, Research, Mental Disorders, Parkinsonism, Brain, Magnetic resonance imaging, General Medicine, Frontotemporal lobar degeneration, Middle Aged, Prognosis, medicine.disease, Magnetic Resonance Imaging, nervous system diseases, Online Only, Neurology, Frontotemporal Dementia, Female, business, Frontotemporal dementia |
| الوصف: | Key Points Question Can widely available measures of atrophy on magnetic resonance imaging increase diagnostic certainty of underlying frontotemporal lobar degeneration (FTLD) and estimate clinical deterioration in the behavioral variant of frontotemporal dementia (bvFTD)? Findings This diagnostic/prognostic study investigated the clinical utility of 5 validated visual atrophy scales (VAS) and the Magnetic Resonance Parkinsonism Index. When combined, VAS showed excellent diagnostic performance for differentiating between bvFTD with high and low confidence of FTLD and for the estimation of longitudinal clinical deterioration, whereas the Magnetic Resonance Parkinsonism Index was increased in bvFTD with underlying 4-repeat tauopathies. Meaning These findings suggest that, in bvFTD, VAS can be used to increase diagnostic certainty of underlying FTLD and estimate longitudinal clinical deterioration. This diagnostic/prognostic study assesses the utility of 6 visual atrophy scales and the Magnetic Resonance Parkinsonism Index in patients with behavioral variant frontotemporal dementia to distinguish those with high vs low confidence of frontotemporal lobar degeneration. Importance The presence of atrophy on magnetic resonance imaging can support the diagnosis of the behavioral variant of frontotemporal dementia (bvFTD), but reproducible measurements are lacking. Objective To assess the diagnostic and prognostic utility of 6 visual atrophy scales (VAS) and the Magnetic Resonance Parkinsonism Index (MRPI). Design, Setting, and Participants In this diagnostic/prognostic study, data from 235 patients with bvFTD and 225 age- and magnetic resonance imaging–matched control individuals from 3 centers were collected from December 1, 1998, to September 30, 2019. One hundred twenty-one participants with bvFTD had high confidence of frontotemporal lobar degeneration (FTLD) (bvFTD-HC), and 19 had low confidence of FTLD (bvFTD-LC). Blinded clinicians applied 6 previously validated VAS, and the MRPI was calculated with a fully automated approach. Cortical thickness and subcortical volumes were also measured for comparison. Data were analyzed from February 1 to June 30, 2020. Main Outcomes and Measures The main outcomes of this study were bvFTD-HC or a neuropathological diagnosis of 4-repeat (4R) tauopathy and the clinical deterioration rate (assessed by longitudinal measurements of Clinical Dementia Rating Sum of Boxes). Measures of cerebral atrophy included VAS scores, the bvFTD atrophy score (sum of VAS scores in orbitofrontal, anterior cingulate, anterior temporal, medial temporal lobe, and frontal insula regions), the MRPI, and other computerized quantifications of cortical and subcortical volumes. The areas under the receiver operating characteristic curve (AUROC) were calculated for the differentiation of participants with bvFTD-HC and bvFTD-LC and controls. Linear mixed models were used to evaluate the ability of atrophy measures to estimate longitudinal clinical deterioration. Results Of the 460 included participants, 296 (64.3%) were men, and the mean (SD) age was 62.6 (11.4) years. The accuracy of the bvFTD atrophy score for the differentiation of bvFTD-HC from controls (AUROC, 0.930; 95% CI, 0.903-0.957) and bvFTD-HC from bvFTD-LC (AUROC, 0.880; 95% CI, 0.787-0.972) was comparable to computerized measures (AUROC, 0.973 [95% CI, 0.954-0.993] and 0.898 [95% CI, 0.834-0.962], respectively). The MRPI was increased in patients with bvFTD and underlying 4R tauopathies compared with other FTLD subtypes (14.1 [2.0] vs 11.2 [2.6] points; P |
| وصف الملف: | application/pdf |
| اللغة: | English |
| DOI: | 10.1001/jamanetworkopen.2021.1290 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6a3007457e3fd12a1d3d2017620533a http://www.cnr.it/prodotto/i/448076 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....d6a3007457e3fd12a1d3d2017620533a |
| قاعدة البيانات: | OpenAIRE |
| DOI: | 10.1001/jamanetworkopen.2021.1290 |
|---|